Quick answer
What is Elamipretide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Elamipretide is a peptide, grouped on this site under Mitochondrial and longevity-associated peptides, and the 12 research records kept here are 4 from studies in rats or mice, 3 from trials in people and 5 that do not state what kind of study it is.
The literature search returned 215 records. This site keeps 12 of them, which is 5.6 per cent of what came back.
What it is
This site puts it in the Mitochondrial and longevity-associated peptides group.
Described in the retrieved records as a mitochondria-targeting peptide, with a mapped mitochondrial protein interaction landscape rather than a single named receptor.[1, 2]
Stated in the titles of the cited 2020 Proceedings of the National Academy of Sciences and 2013 Journal of the American Society of Nephrology papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 3 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 203 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences of the United States of America (2020). pmid:32554501
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology : JASN (2013). pmid:23813215